Biocon addresses merger rumors for Biocon Biologics subsidiary

On November 14, 2025, Biocon Limited confirmed it is evaluating strategic options for its unlisted subsidiary, Biocon Biologics Limited (BBL), following media reports about a potential merger between BBL and Biocon, an IPO, and share swap options. This statement references a previous press release from May 08, 2025, in which the company announced the formation of a committee to explore restructuring options, including the merger of BBL and Biocon Limited.

The committee's ongoing evaluation considers legal and tax implications, and any decision will be contingent on obtaining all necessary approvals from the board, shareholders, and relevant regulatory bodies. The company stressed its commitment to adhering to all applicable laws and contractual terms during this process.

Biocon stated that, at this stage, there is no material event or information requiring disclosure under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reiterated its commitment to high standards of governance and will continue to make appropriate disclosures as required.